



Radius Health, Inc.
Investor Relations Department
950 Winter St, North Building 1st Floor
North Building 1st Floor
Waltham, MA 02451
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: RDUS

Last Trade:	35.17
Trade Time:	4:00 PM ET Sep 22, 2017
Change:	0.32 (+0.918%)
Day Range	34.36 - 35.44
52-Week Range	31.58 - 59.22
Volume	521,719

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical ... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Sep 22, 2017
[Radius Health to Present at Cantor Annual Global Healthcare Conference](#)
- Sep 10, 2017
[Radius Health Presents Positive Data for TYMLOS™ \(abaloparatide\) Injection from the ACTIVEExtend Trial at ASBMR 2017 Annual Meeting](#)
- Sep 7, 2017
[Radius Health to Present at Morgan Stanley 15th Annual Global Healthcare Conference](#)
- Sep 1, 2017
[Radius Health to Present Eight Abstracts at the American Society of Bone and Mineral Research \(ASBMR\) 2017 Annual Meeting Including Results of the ACTIVE and ACTIVEExtend Trials for TYMLOS™ \(abaloparatide\) Injection](#)
- Aug 10, 2017
[New National Survey Reveals 82 Percent of Postmenopausal Women Miss Critical Connection Between Osteoporosis and Bone Fractures](#)

Upcoming Events [\[View all \]](#)

- Sep 25, 2017 8:35 AM ET
[Cantor Fitzgerald Global Healthcare Conference](#)
- Financials [\[View all \]](#)
[Second Quarter Financial Results](#)
- Feb 24, 2017
[Annual Report \(10-K\)](#)
- Apr 21, 2017
[Proxy Statement \(DEF 14A\)](#)
- Aug 4, 2017
[Quarterly Report \(10-Q\)](#)
- May 2, 2017
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016
[Quarterly Report \(10-Q\)](#)